Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05228990
Other study ID # CI2021A015
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 14, 2022
Est. completion date December 31, 2023

Study information

Verified date February 2023
Source Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Contact Yang Li, MM
Phone +8601088001132
Email liyang99280@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Non-pharmaceutical therapies, such as acupuncture, hydrotherapy, and meditative exercises (such as Qigong (including Tai Chi and Ba-Duan-Jin), have been shown to reduce pain and improve physical function. The management recommendations of fibromyalgia issued by the European Union, Canada, Germany and Israel have all affirmed the "first-line" role of Non-pharmaceutical therapy. Because of its good efficacy and safety, acupuncture therapy has been recommended in the management guidelines and has broad application prospects. Warm acupuncture is a therapy combining acupuncture and moxibustion, which is widely used in the treatment of various painful diseases in China, especially for cold-sensitive patients . This study aims to observe the safety and effectiveness of warm acupuncture in the treatment of cold-sensitive fibromyalgia patients, in order to provide a more alternative non-drug therapy for this particular type of patients with fibromyalgia .


Recruitment information / eligibility

Status Recruiting
Enrollment 38
Est. completion date December 31, 2023
Est. primary completion date November 30, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Meet the 1990 American College of Rheumatology (ACR) Research Classification Criteria for fibromyalgia; 2. Be over 18 years of age; 3. The type and dose of drugs used for fibromyalgia should be stable for at least 2 weeks; 4. The VAS score of item 10 (sensitivity to cold) in FIQR scale ?4 points; 5. Sign informed consent. Exclusion Criteria: 1. Patients suffering from systemic or local acute infectious diseases; 2. Patients with severe visceral diseases or physical weakness who cannot tolerate acupuncture treatment; 3. Pregnant women.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
warm acupunctrue
The sterile acupuncture needle (0.3mm×40mm) is taken, and the acupuncture needle is vertically inserted into the corresponding depth of the acupoint. After the needle is transported to "get qi", moxibustion will be added at acupoints. The moxibustion distance is about 3cm from the skin, and the local temperature is warm and the patient felt comfortable with the skin. Replace it after burning out. During the acupuncture treatment, in order to avoid burns, it is necessary to strictly control the distance between moxibustion and skin. In the supine position, cardboard should be placed between moxibustion and skin to prevent burns, and ashes should be removed after moxibustion is completely burned. The needle is left for 20 minutes.

Locations

Country Name City State
China Guang'anmen Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The change of the VAS score for item 10 (susceptibility to cold) of the modified fibromyalgia Impact Questionnaire from baseline. range from 0 to 10 cm with higher score indicating more sensitive to cold. Baseline, week4, week8, week12, week16
Secondary The change of the revised Fibromyalgia Impact Questionnaire (FIQR) from baseline A self-administered questionnaire with 10 subscales, measuring fibromyalgia symptoms and function domains. FIQR total score ranges from 0 to 100, with higher scores indicating more severe symptoms. Baseline, week4, week8, week12, week16
Secondary The change of the Visual Analogue Scale (VAS) for pain from baseline. Pain VAS, range, 0 to 10 cm, where higher scores indicated the perceived pain to be more severe. Baseline, week4, week8, week12, week16
Secondary The change of the Multidimensional Fatigue Inventory-20 (MFI-20) from baseline. The Multidimensional Fatigue Inventory-20 (MFI-20) measures fatigue severity. The MFI-20 total score ranges from 0 to 80, with higher scores indicate more severe fatigue. Baseline, week4, week8, week12, week16
Secondary The change of the Perceived Stress Scale (PSS) from baseline. The Perceived Stress Scale (PSS) is for measuring the perception of stress and The Perceived Stress Scale (PSS) is for measuring the perception of stress and current levels of experienced stress. Scores range from 0 to 56, with higher total score indicating a greater degree of symptom severity Baseline, week4, week8, week12, week16
Secondary The change of the Hamilton Anxiety Scale(HAMA) from baseline. he Hamilton Anxiety Scale is used to assess the severity of anxiety symptoms and consists of 14 items, with higher scores indicating greater anxiety Baseline, week4, week8, week12, week16
Secondary The change of the Beck II Depression Inventory (BDI) from baseline. The Beck II Depression Inventory (BDI) assesses the severity of depressive symptoms. Scores range from 0 to 39, with higher scores indicate a greater degree of depression severity. Baseline, week4, week8, week12, week16
Secondary The change of the Short Form-36 Health Status Questionnaire (SF-36) from baseline. The Short Form-36 Health Status Questionnaire (SF-36), which measured health-related quality of life (range, 0 to 100, with higher scores indicating better perceived health status Baseline, week4, week8, week12, week16
Secondary The change of the Minimum Mental State Examination(MMSE) from baseline. The Minimum Mental State Examination(MMSE) scores range from 0 to 30, with higher scores indicating better cognitive function Baseline, week4, week8, week12, week16
Secondary The change of the Pittsburgh Sleep Quality Index (PSQI) from baseline. Scores on the Pittsburgh Sleep Quality Index (PSQI) range from 0 to 21, with higher scores indicating worse sleep quality. Baseline, week4, week8, week12, week16
Secondary Global Impression of Change (PGIC) questionnaire evaluated at week 16. A questionnaire determine any change in overall symptom status from the beginning of the study to its conclusion (score range, 1 [very much improved] to 7 [very much worse). week16
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05659862 - Digitally Assisted Behavioral Physical Activity Intervention in Fibromyalgia N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT03042728 - Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program N/A
Recruiting NCT06097091 - Effects and Mechanisms of Pain Neuroscience Education in Patients With Fibromyalgia N/A
Recruiting NCT04554784 - Effectiveness of Bowen Therapy for Pain Management in Patients With Fibromyalgia N/A
Completed NCT03300635 - Metabolism, Muscle Function and Psychological Factors in Fibromyalgia N/A
Recruiting NCT06166563 - Exercise, Irritable Bowel Syndrome and Fibromyalgia N/A
Completed NCT03227952 - Sensory Stimulation in Fibromyalgia N/A
Completed NCT03166995 - Postural Exercises in Women With Fibromyalgia N/A
Recruiting NCT06237595 - Vagus Nerve Stimulation in Fibromyalgia N/A
Completed NCT01888640 - Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST) N/A
Completed NCT03641495 - Pain Education and Therapeutic Exercise for Fibromyalgia N/A
Recruiting NCT05581628 - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Active, not recruiting NCT05128162 - Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia Phase 2
Completed NCT04674878 - Comparison of Muscle Energy Techniques and Breathing Exercises for Functional Improvement in Fibromyalgia N/A
Active, not recruiting NCT04084795 - Augmentation of EMDR With tDCS in the Treatment of Fibromyalgia N/A
Completed NCT03129906 - Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients N/A
Completed NCT05058911 - Exposure-based Cognitive Behavior Therapy vs Traditional Cognitive Behavior Therapy for Fibromyalgia N/A
Recruiting NCT04571528 - Effectiveness of VIRTUAL FIBROWALK STUDY N/A
Recruiting NCT04571853 - New Educational Tool for FM N/A